{"entity":{"id":"nct06904378","kind":"trial","name":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","aka":[],"tldr":"A phase 1/2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Washington University School of Medicine, now recruiting.","summary":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma is a phase 1/2, randomised interventional study registered as NCT06904378 by Washington University School of Medicine, with a registry enrolment figure of 61 participants, started 2026-03-25 and due to reach its primary completion in 2028-09-30. Interventions recorded: ONT01; Gemcitabine; Nab paclitaxel. Conditions listed: Metastatic Pancreatic Ductal Adenocarcinoma. Primary outcome: Recommended phase II dose (RP2D) (Phase I only); Number of participants with dose-limiting toxicities (DLTs) (Phase I only); Progression-free rate at 6 months (RP2D participants in Phase I and Phase II participants only). Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed adenocarcinoma of the pancreas\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06904378","url":"https://clinicaltrials.gov/study/NCT06904378"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06904378","phase":"1/2","setting":"Phase I/II Clinical Trial of ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells","sponsor":"Washington University School of Medicine","enrolled":61,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06904378/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}